Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Carreño-Tarragona G.
  • Gil-Manso R.
  • Hernández-Boluda J.C.
  • Martínez-Ávila J.C.
  • Bellosillo B.
  • Pérez-López R.
  • Segura A.
  • Ferrer-Marín F.
  • Arellano-Rodrigo E.
  • Angona A.
  • García-Gutiérrez V.
  • Noya M.S.
  • Blanco Á.
  • Zamora L.
  • Navarro M.
  • Senín A.
  • Magro E.
  • Pastor-Galán I.
  • Mata-Vázquez M.I.
  • Morales M.L.
  • Cuevas B.
  • Vélez P.
  • Martínez-Bilbao C.
  • Colmenares R.
  • Alonso J.M.
  • Pérez-Encinas M.
  • Caballero-Navarro G.
  • Cortés M.Á.
  • Santaliestra M.
  • Raya J.M.
  • Blanco-Sánchez A.
  • Hernández-Rivas J.M.
  • Martínez-López J.
  • Ayala R.
  • Álvarez-Larrán A.

Grupos

Abstract

Triple-negative essential thrombocythemia (TN-ET) represents a diagnostic and therapeutic challenge. The aim of the present study was to identify prognostic factors useful for tailoring treatment. 241 TN-ET patients with myeloid panel sequencing and confirmatory bone marrow biopsy were selected. Pathogenic/likely pathogenic variants were identified in 19.5% of patients. Mutation carriers were older (median age 66 years vs. 53, p < 0.001) and had a higher frequency of prior thrombosis (19.6% vs. 6.5%, p = 0.013). Presence of pathogenic/likely pathogenic variants was associated with leukemic progression (HR 12.608; 95% CI: 2.616–60.775, p = 0.002) and lower overall survival (HR 3.008; 95% CI: 1.43–6.327, p = 0.004). ASXL1 (p = 0.004), CBL (p < 0.001), EZH2 (p < 0.001), and ZRSR2 (p < 0.001) mutations were associated with inferior leukemia-free survival. Age over 60 years, previous thrombosis, and cardiovascular risk factors were associated with higher thrombotic risk. Revised IPSET-thrombosis was useful for risk stratification (10-year probability of overall thrombosis: 30%, 15%, and 6% for high-, intermediate-, and very-low risk patients, respectively, p < 0.001). ARTS score refined arterial thrombosis stratification (10 years probability: 25% and 6% for high- and low-risk, respectively, p < 0.001). Progression to myelofibrosis was a rare event in this cohort (2.5%). These results highlight the biological and prognostic relevance of molecular profile in TN-ET. © The Author(s) 2026.

Datos de la publicación

ISSN/ISSNe:
0887-6924, 1476-5551

LEUKEMIA  SPRINGERNATURE

Tipo:
Article
Páginas:
1968-1976
PubMed:
42443413
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
4,030 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Disease Risk Factors; Humans; Male; Middle Aged; Mutation; Prognosis; Risk Factors; Survival Rate; Thrombocythemia, Essential; adult; aged; cardiovascular disease; complication; etiology; female; genetics; heart disease risk factor; human; male; middle aged; mutation; pathology; prognosis; risk factor; survival rate; thrombocythemia; very elderly

Cita

Compartir